Carbamazepine and methylphenidate [1]

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 38, Issue 6, 1999, Pages 637-

  Gross Tsur, V ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ANTICONVULSANT THERAPY; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; ENZYME INDUCTION; EPILEPSY; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION;

ANTICONVULSANTS; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; METHYLPHENIDATE;

EID: 0033146889     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199906000-00001     Document Type: Letter

References (2)

1. D Behar J Schaller S Spreat Extreme reduction of methylphenidate levels by carbamazepine (letter) J Am Acad Child Adolesc Psychiatry 3 1998 1128 1129
2. V Gross-Tsur O Manor J van der Meere A Joseph RS Shalev Epilepsy and attention-deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 130 1997 40 44